Spondyloarthritis & psoriatic arthritis
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
Authors' conclusion
Two-thirds of patients remained on TNFi at 12months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.
Study context
- Population
- Real-world PsA patients initiating a 2nd or 3rd TNFi, 12 European registries12 European registries
- Participants
- 5,233 vs 1,906
- Exposure
- 2nd TNFi vs 3rd TNFi, by reason for discontinuation of the previous TNFi
- 2nd TNFin = 5,233
- 3rd TNFin = 1,906
- Outcome
- Retention rate
- Follow-up
- 12 months
Methodological detailspooled data from 12 European registries, prospectively collected routine care data, Kaplan-Meier estimation, adjusted Cox regression, LUNDEX-adjusted
- Pooled data from 12 European registries
- Prospectively collected routine care data
- Kaplan-Meier estimation
- Adjusted Cox regression
- LUNDEX-adjusted
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Retention rate by reason for stopping previous TNFi: AE / LOE · 12 months 2nd TNFi 66%/65% · 3rd TNFi 65%/63%
AE
LOE
Retention rate by previous TNFi stopped due to LOE after less vs more than 24 weeks · 12 months 2nd TNFi 54%/69% · 3rd TNFi 58%/65%
LOE <24 weeks
LOE >24 weeks
DAS28 remission, crude/LUNDEX-adjusted · 6 months 2nd TNFi 48%/35% · 3rd TNFi 38%/27%
Crude
LUNDEX-adjusted
DAPSA28 remission, crude/LUNDEX-adjusted · 6 months 2nd TNFi 19%/14% · 3rd TNFi 14%/10%
Crude
LUNDEX-adjusted
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →